Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing toluene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer was finally isolated by means of chiral HPLC.

Condensation of 6'-amino-2,2,2,2',3'-pentafluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing xylene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer was isolated by means of chiral HPLC.

Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing toluene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer (VI) was then isolated by means of chiral HPLC. Finally, reduction of the triple bond of (VI) with LiAlH4 furnished the corresponding olefin.

DPC-083 is directly obtained by reduction of (?-6-chloro-4(S)-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one (I), DPC-961, with lithium aluminum hydride in 1,2-dichlorobenzene/THF.

DPC-961 (I) can be obtained by several different related ways: 1) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine in THF, followed by desilylation with tetrabutylammonium fluoride in THF, provides the quinazoline derivative (III), which is dehydrated employing molecular sieves in refluxing toluene to yield the imine (IV). Treatment of compound (IV) with lithium cyclopropylacetylide (V) in THF in the presence of BF3.Et2O gives the racemic adduct (VI). Finally, the desired (S)-enantiomer (I) is isolated by means of chiral HPLC . 2) Condensation of 6-chloro-4-(trifluoromethyl)quinazolin-2(1H)-one (IV) with lithium cyclopropylacetylide (V) catalyzed by the chiral auxiliary (X) in toluene/THF gives directly DPC-961. The chiral auxiliary (X) can be synthesized as follows: Epoxidation of (+)-3-carene (VII) with MCPBA in dichloromethane gives the corresponding epoxide (VIII), which is then condensed with morpholine (IX) by means of MgBr2 as catalyst.

Condensation of 6'-amino-2,2,2,2',3'-pentafluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing xylene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer (VI) was then isolated by means of chiral HPLC. Finally, reduction of the triple bond of (VI) with LiAlH4 furnished the corresponding olefin.

The condensation of 6-chloro-4-(trifluoromethyl)quinazolin-2(1H)-one (V) with lithium cyclopropylacetylene (VI) (LiHMDS is used as strong base) catalyzed by the chiral moderator (IV) in toluene/THF gives the target compound. The chiral moderator (IV) has been obtained as follows: The epoxidation of (+)-3-carene (I) with MCPBA in dichloromethane gives the corresponding epoxide (II), which is then condensed with morpholine (III) by means of MgBr2 as catalyst.

The condensation of 5,6-difluoro-4-(trifluoromethyl)quinazolin-2(1H)-one (V) with lithium cyclopropylacetylene (VI) (LiHMDS is used as strong base) catalyzed by the chiral moderator (IV) in toluene/THF gives the target compound with an enantiomeric excess of 94%, which increases up to 99.6% after working up (crystallization in heptane). The chiral moderator (IV) has been obtained as follows: The epoxidation of (+)-3-carene (I) with MCPBA in dichloromethane gives the corresponding epoxide (II), which is then condensed with morpholine (III) using MgBr as a catalyst.

DPC-961 (I) can be obtained by several different related ways: 1) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine in THF, followed by desilylation with tetrabutylammonium fluoride in THF, provides the quinazoline derivative (III), which is dehydrated employing molecular sieves in refluxing toluene to yield the imine (IV). Treatment of compound (IV) with lithium cyclopropylacetylide (V) in THF in the presence of BF3.Et2O gives the racemic adduct (VI). Finally, the desired (S)-enantiomer (I) is isolated by means of chiral HPLC . 2) Condensation of 6-chloro-4-(trifluoromethyl)quinazolin-2(1H)-one (IV) with lithium cyclopropylacetylide (V) catalyzed by the chiral auxiliary (X) in toluene/THF gives directly DPC-961. The chiral auxiliary (X) can be synthesized as follows: Epoxidation of (+)-3-carene (VII) with MCPBA in dichloromethane gives the corresponding epoxide (VIII), which is then condensed with morpholine (IX) by means of MgBr2 as catalyst.

The condensation of 4-chloro-2-(2,2,2-trifluoro-1,1-dihydroxyethyl)aniline (I) with (R)-1-phenylethyl isocyanate (II) at low temperature gives a mixture of the urea (III) and tetrahydroquinazolinone (IV). Without isolation the urea (III) is cyclized to the tetrahydroquinazolinone (IV) by heating at 60 C. The dehydration of (IV) by means of SOCl2 and TEA in toluene affords the quinazolinone (V), which, without isolation, is condensed with the cyclopropylacetylide (VI) in THF to provide the alkylated tetrahydroquinazolinone (VII). Finally, this compound is deprotected from the chiral auxiliary by means of TFA or formic acid.

DPC-961 (I) can be obtained by several different related ways: 3) Condensation of 4-chloro-2-(2,2,2-trifluoro-1,1-dihydroxyethyl)aniline (XI) with (R)-1-phenylethyl isocyanate (XII) by means of HCl at low temperature gives a mixture of the urea (XIII) and tetrahydroquinazolinone (XIV). Without isolation, urea (XIII) is cyclized to the tetrahydroquinazolinone (XIV) by heating at 60 C. Dehydration of (XIV) by means of SOCl2 and Et3N in toluene affords the quinazolinone (XV), which, without isolation, is condensed with the Grignard reagent bromomagnesium cyclopropylacetylide (XVI) in THF to provide the alkylated tetrahydroquinazolinone (XVII). Finally, compound (XVII) is deprotected from the chiral auxiliary by means of TFA or formic acid. 4) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with (R)-1-phenylethyl isocyanate (XII) by means of either HCl in THF or TMSCl/THF in toluene, followed by heating at 60-65 C, provides the tetrahydroquinazolinone (XIX). Dehydration of (XIX) with SOCl2 and Et3N or NMM in toluene affords quinazolinone (XV), which, without isolation, is condensed with the Grignard reagent chloromagnesium cyclopropylacetylide (XX) to give the tetrahydroquinazoline (XVII). Finally, this compound is treated with TFA or formic acid as before.

Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing toluene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer was finally isolated by means of chiral HPLC.

Condensation of 6'-amino-2,2,2,2',3'-pentafluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing xylene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer was isolated by means of chiral HPLC.

Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing toluene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer (VI) was then isolated by means of chiral HPLC. Finally, reduction of the triple bond of (VI) with LiAlH4 furnished the corresponding olefin.

DPC-083 is directly obtained by reduction of (?-6-chloro-4(S)-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one (I), DPC-961, with lithium aluminum hydride in 1,2-dichlorobenzene/THF.

DPC-961 (I) can be obtained by several different related ways: 1) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine in THF, followed by desilylation with tetrabutylammonium fluoride in THF, provides the quinazoline derivative (III), which is dehydrated employing molecular sieves in refluxing toluene to yield the imine (IV). Treatment of compound (IV) with lithium cyclopropylacetylide (V) in THF in the presence of BF3.Et2O gives the racemic adduct (VI). Finally, the desired (S)-enantiomer (I) is isolated by means of chiral HPLC . 2) Condensation of 6-chloro-4-(trifluoromethyl)quinazolin-2(1H)-one (IV) with lithium cyclopropylacetylide (V) catalyzed by the chiral auxiliary (X) in toluene/THF gives directly DPC-961. The chiral auxiliary (X) can be synthesized as follows: Epoxidation of (+)-3-carene (VII) with MCPBA in dichloromethane gives the corresponding epoxide (VIII), which is then condensed with morpholine (IX) by means of MgBr2 as catalyst.

Condensation of 6'-amino-2,2,2,2',3'-pentafluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing xylene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer (VI) was then isolated by means of chiral HPLC. Finally, reduction of the triple bond of (VI) with LiAlH4 furnished the corresponding olefin.

Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing toluene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer was finally isolated by means of chiral HPLC.

Condensation of 6'-amino-2,2,2,2',3'-pentafluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing xylene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer was isolated by means of chiral HPLC.

Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing toluene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer (VI) was then isolated by means of chiral HPLC. Finally, reduction of the triple bond of (VI) with LiAlH4 furnished the corresponding olefin.

DPC-083 is directly obtained by reduction of (?-6-chloro-4(S)-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one (I), DPC-961, with lithium aluminum hydride in 1,2-dichlorobenzene/THF.

DPC-961 (I) can be obtained by several different related ways: 1) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine in THF, followed by desilylation with tetrabutylammonium fluoride in THF, provides the quinazoline derivative (III), which is dehydrated employing molecular sieves in refluxing toluene to yield the imine (IV). Treatment of compound (IV) with lithium cyclopropylacetylide (V) in THF in the presence of BF3.Et2O gives the racemic adduct (VI). Finally, the desired (S)-enantiomer (I) is isolated by means of chiral HPLC . 2) Condensation of 6-chloro-4-(trifluoromethyl)quinazolin-2(1H)-one (IV) with lithium cyclopropylacetylide (V) catalyzed by the chiral auxiliary (X) in toluene/THF gives directly DPC-961. The chiral auxiliary (X) can be synthesized as follows: Epoxidation of (+)-3-carene (VII) with MCPBA in dichloromethane gives the corresponding epoxide (VIII), which is then condensed with morpholine (IX) by means of MgBr2 as catalyst.

Condensation of 6'-amino-2,2,2,2',3'-pentafluoroacetophenone (I) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine, followed by desilylation with tetrabutylammonium fluoride provided the quinazoline derivative (II). Dehydration of the tertiary alcohol of (II) to afford imine (III) was carried out employing molecular sieves in refluxing xylene. Subsequent addition of lithium cyclopropylacetylide (IV) to (III) in the presence of BF3-Et2O yielded the racemic adduct (V). The desired (S)-enantiomer (VI) was then isolated by means of chiral HPLC. Finally, reduction of the triple bond of (VI) with LiAlH4 furnished the corresponding olefin.

The condensation of 4-chloro-2-(2,2,2-trifluoro-1,1-dihydroxyethyl)aniline (I) with (R)-1-phenylethyl isocyanate (II) at low temperature gives a mixture of the urea (III) and tetrahydroquinazolinone (IV). Without isolation the urea (III) is cyclized to the tetrahydroquinazolinone (IV) by heating at 60 C. The dehydration of (IV) by means of SOCl2 and TEA in toluene affords the quinazolinone (V), which, without isolation, is condensed with the cyclopropylacetylide (VI) in THF to provide the alkylated tetrahydroquinazolinone (VII). Finally, this compound is deprotected from the chiral auxiliary by means of TFA or formic acid.

DPC-961 (I) can be obtained by several different related ways: 3) Condensation of 4-chloro-2-(2,2,2-trifluoro-1,1-dihydroxyethyl)aniline (XI) with (R)-1-phenylethyl isocyanate (XII) by means of HCl at low temperature gives a mixture of the urea (XIII) and tetrahydroquinazolinone (XIV). Without isolation, urea (XIII) is cyclized to the tetrahydroquinazolinone (XIV) by heating at 60 C. Dehydration of (XIV) by means of SOCl2 and Et3N in toluene affords the quinazolinone (XV), which, without isolation, is condensed with the Grignard reagent bromomagnesium cyclopropylacetylide (XVI) in THF to provide the alkylated tetrahydroquinazolinone (XVII). Finally, compound (XVII) is deprotected from the chiral auxiliary by means of TFA or formic acid. 4) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with (R)-1-phenylethyl isocyanate (XII) by means of either HCl in THF or TMSCl/THF in toluene, followed by heating at 60-65 C, provides the tetrahydroquinazolinone (XIX). Dehydration of (XIX) with SOCl2 and Et3N or NMM in toluene affords quinazolinone (XV), which, without isolation, is condensed with the Grignard reagent chloromagnesium cyclopropylacetylide (XX) to give the tetrahydroquinazoline (XVII). Finally, this compound is treated with TFA or formic acid as before.

DPC-083 is directly obtained by reduction of (?-6-chloro-4(S)-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one (I), DPC-961, with lithium aluminum hydride in 1,2-dichlorobenzene/THF.

DPC-961 (I) can be obtained by several different related ways: 1) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with trimethylsilyl isocyanate in the presence of dimethylaminopyridine in THF, followed by desilylation with tetrabutylammonium fluoride in THF, provides the quinazoline derivative (III), which is dehydrated employing molecular sieves in refluxing toluene to yield the imine (IV). Treatment of compound (IV) with lithium cyclopropylacetylide (V) in THF in the presence of BF3.Et2O gives the racemic adduct (VI). Finally, the desired (S)-enantiomer (I) is isolated by means of chiral HPLC . 2) Condensation of 6-chloro-4-(trifluoromethyl)quinazolin-2(1H)-one (IV) with lithium cyclopropylacetylide (V) catalyzed by the chiral auxiliary (X) in toluene/THF gives directly DPC-961. The chiral auxiliary (X) can be synthesized as follows: Epoxidation of (+)-3-carene (VII) with MCPBA in dichloromethane gives the corresponding epoxide (VIII), which is then condensed with morpholine (IX) by means of MgBr2 as catalyst.

DPC-961 (I) can be obtained by several different related ways: 3) Condensation of 4-chloro-2-(2,2,2-trifluoro-1,1-dihydroxyethyl)aniline (XI) with (R)-1-phenylethyl isocyanate (XII) by means of HCl at low temperature gives a mixture of the urea (XIII) and tetrahydroquinazolinone (XIV). Without isolation, urea (XIII) is cyclized to the tetrahydroquinazolinone (XIV) by heating at 60 C. Dehydration of (XIV) by means of SOCl2 and Et3N in toluene affords the quinazolinone (XV), which, without isolation, is condensed with the Grignard reagent bromomagnesium cyclopropylacetylide (XVI) in THF to provide the alkylated tetrahydroquinazolinone (XVII). Finally, compound (XVII) is deprotected from the chiral auxiliary by means of TFA or formic acid. 4) Condensation of 2'-amino-5'-chloro-2,2,2-trifluoroacetophenone (II) with (R)-1-phenylethyl isocyanate (XII) by means of either HCl in THF or TMSCl/THF in toluene, followed by heating at 60-65 C, provides the tetrahydroquinazolinone (XIX). Dehydration of (XIX) with SOCl2 and Et3N or NMM in toluene affords quinazolinone (XV), which, without isolation, is condensed with the Grignard reagent chloromagnesium cyclopropylacetylide (XX) to give the tetrahydroquinazoline (XVII). Finally, this compound is treated with TFA or formic acid as before.